TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX)

This dataset includes data for 189 trial participants with HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) who took part in the phase 3 multi-centre, open-label randomised trial of weekly cetuximab and RT versus weekly cisplatin and RT for patients with locoregionally advanced HPV-OPSCC. Participants were recruited at sites in Australia and New Zealand and includes data from registration on study, and up to 5 years in follow up. The study commenced in June 2013 and conducted the last patient last visit in Aug 2023. Dataset includes Timepoints at 3, 6, 9, 12 months and yearly to 5 years, QOL, Cancer Australia demographic data includes: Date of birth.